RT Journal
A1 Goyder E, Irwig L
T1 SCreening for type 2 diabetes
JF JAMA
JO JAMA
YR 1999
FD June 2
VO 281
IS 21
SP 1986
OP 1988
DO 10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
UL http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602
AB 
First, the authors assume that screening merely brings forward the date
of diagnosis. Their model and their estimate of the time between onset
and clinical diagnosis are based on studies of clinically diagnosed
cases. However, a population identified by screening would include many
people whose condition would never be clinically apparent and who will
die, mainly of cardiovascular disease (CVD), before clinical diagnosis
and long before they would develop long-term microvascular
complications. The model therefore may overestimate the risks of
end-stage microvascular disease for screening-detected cases.